Tirzepatide is a dual incretin receptor agonist that targets both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual mechanism represents a next-generation approach to metabolic regulation, offering potent effects on glycemic control, appetite suppression, and body-weight reduction.
Tirzepatide (20 Mg)
Tirzepatide simultaneously activates GLP-1 and GIP receptors, producing complementary and synergistic metabolic effects:
• Enhances glucose-dependent insulin secretion
• Suppresses glucagon release, reducing hepatic glucose output
• Slows gastric emptying, promoting prolonged satiety
• Reduces appetite and caloric intake via central nervous system pathways
• Improves insulin sensitivity, particularly through GIP receptor activity
The dual-agonist profile allows tirzepatide to achieve greater metabolic efficiency than GLP-1–only therapies.
